Interleukin-23 deficiency leads to impaired wound healing and adverse prognosis after myocardial infarction

Circulation: Heart Failure

Volumn 7, Issue 1, 2014, Pages 161-171

  Savvatis, Konstantinos ^a,b   Pappritz, Kathleen ^a   Becher, Peter Moritz ^e   Lindner, Diana ^e   Zietsch, Christin ^a   Volk, Hans Dieter ^a,b,c   Westermann, Dirk ^e   Schultheiss, Heinz Peter ^f   Tschöpe, Carsten ^a,b,d  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b Berlin Brandenburg Center for Regenerative Therapies   (Germany)

^c Institute for Medical Immunology   (Germany)

^d DZHK GERMAN CENTRE FOR CARDIOVASCULAR RESEARCH   (Germany)

^e UNIVERSITY HEART CENTER HAMBURG   (Germany)

^f FREIE UNIVERSITÄT BERLIN   (Germany)

Author keywords

Fibroblasts; Interleukin 23; Left ventricular remodeling; Myocardial infarction

Indexed keywords

ALPHA SMOOTH MUSCLE ACTIN; COLLAGEN TYPE 1; COLLAGEN TYPE 3; GAMMA INTERFERON; INTERLEUKIN 17; INTERLEUKIN 23; INTERLEUKIN 23P19; MATRIX METALLOPROTEINASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; STAT3 PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; C57BL 6 MOUSE; CELL DIFFERENTIATION; CELL INFILTRATION; CELL MIGRATION; COMPARATIVE STUDY; CONTROLLED STUDY; FIBROBLAST; GENE EXPRESSION; HEALING IMPAIRMENT; HEART INFARCTION; HEART LEFT VENTRICLE; IMMUNOCOMPETENT CELL; IMMUNOHISTOLOGY; INTERLEUKIN 23 DEFICIENCY; MALE; MOUSE; MYOCARDITIS; MYOFIBROBLAST; NONHUMAN; PRIORITY JOURNAL; PROGNOSIS; PROTEIN DEFECT; PROTEIN DEPHOSPHORYLATION; RNA ISOLATION; TH1 CELL; WESTERN BLOTTING; WILD TYPE; WOUND HEALING; WOUND HEALING IMPAIRMENT; ZYMOGRAPHY;

FIBROBLASTS; INTERLEUKIN-23; LEFT VENTRICULAR REMODELING; MYOCARDIAL INFARCTION;

ANIMALS; CELL DIFFERENTIATION; CELL MOVEMENT; CELLS, CULTURED; CICATRIX; CYTOKINES; DISEASE MODELS, ANIMAL; FIBROBLASTS; INTERFERON-GAMMA; INTERLEUKIN-17; INTERLEUKIN-23; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MYOCARDIAL INFARCTION; PROGNOSIS; WOUND HEALING;

EID: 84896124089     PISSN: 19413289     EISSN: 19413297     Source Type: Journal    
DOI: 10.1161/CIRCHEARTFAILURE.113.000604     Document Type: Article

References (35)

1. Frangogiannis NG. Regulation of the inflammatory response in cardiac repair. Circ Res. 2012;110:159-173.
2. Hofmann U, Beyersdorf N, Weirather J, Podolskaya A, Bauersachs J, Ertl G, Kerkau T, Frantz S. Activation of CD4+ T lymphocytes improves wound healing and survival after experimental myocardial infarction in mice. Circulation. 2012;125:1652-1663.
3. Timmers L, Sluijter JP, van Keulen JK, Hoefer IE, Nederhoff MG, Goumans MJ, Doevendans PA, van Echteld CJ, Joles JA, Quax PH, Piek JJ, Pasterkamp G, de Kleijn DP. Toll-like receptor 4 mediates maladaptive left ventricular remodeling and impairs cardiac function after myocardial infarction. Circ Res. 2008;102:257-264.
4. Koch M, Savvatis K, Scheeler M, Dhayat S, Bonaventura K, Pohl T, Riad A, Bulfone-Paus S, Schultheiss HP, Tschöpe C. Immunosuppression with an interleukin-2 fusion protein leads to improved LV function in experimental ischemic cardiomyopathy. Int Immunopharmacol. 2010;10:207-212.
5. Zhu J, Paul WE. CD4 T cells: fates, functions, and faults. Blood. 2008;112:1557-1569.
6. Vignali DA, Kuchroo VK. IL-12 family cytokines: immunological playmakers. Nat Immunol. 2012;13:722-728.
7. Simon T, Taleb S, Danchin N, Laurans L, Rousseau B, Cattan S, Montely JM, Dubourg O, Tedgui A, Kotti S, Mallat Z. Circulating levels of interleukin- 17 and cardiovascular outcomes in patients with acute myocardial infarction. Eur Heart J. 2013;34:570-577.
8. Zhao Z, Wu Y, Cheng M, Ji Y, Yang X, Liu P, Jia S, Yuan Z. Activation of Th17/Th1 and Th1, but not Th17, is associated with the acute cardiac event in patients with acute coronary syndrome. Atherosclerosis. 2011;217:518-524.
9. Itoh S, Kimura N, Axtell RC, Velotta JB, Gong Y, Wang X, Kajiwara N, Nambu A, Shimura E, Adachi H, Iwakura Y, Saito H, Okumura K, Sudo K, Steinman L, Robbins RC, Nakae S, Fischbein MP. Interleukin-17 accelerates allograft rejection by suppressing regulatory T cell expansion. Circulation. 2011;124(11 Suppl):S187-S196.
10. Yang F, Wu WF, Yan YL, Pang Y, Kong Q, Huang YL. Expression of IL- 23/Th17 pathway in a murine model of Coxsackie virus B3-induced viral myocarditis. Virol J. 2011;8:301.
11. Yuan J, Yu M, Lin QW, Cao AL, Yu X, Dong JH, Wang JP, Zhang JH, Wang M, Guo HP, Cheng X, Liao YH. Th17 cells contribute to viral replication in coxsackievirus B3-induced acute viral myocarditis. J Immunol. 2010;185:4004-4010.
12. Westermann D, Riad A, Lettau O, Roks A, Savvatis K, Becher PM, Escher F, Jan Danser AH, Schultheiss HP, Tschöpe C. Renin inhibition improves cardiac function and remodeling after myocardial infarction independent of blood pressure. Hypertension. 2008;52:1068-1075.
13. Westermann D, Savvatis K, Lindner D, Zietsch C, Becher PM, Hammer E, Heimesaat MM, Bereswill S, Völker U, Escher F, Riad A, Plendl J, Klingel K, Poller W, Schultheiss HP, Tschöpe C. Reduced degradation of the chemokine MCP-3 by matrix metalloproteinase-2 exacerbates myocardial inflammation in experimental viral cardiomyopathy. Circulation. 2011;124:2082-2093.
14. Savvatis K, van Linthout S, Miteva K, Pappritz K, Westermann D, Schefold JC, Fusch G, Weithäuser A, Rauch U, Becher PM, Klingel K, Ringe J, Kurtz A, Schultheiss HP, Tschöpe C. Mesenchymal stromal cells but not cardiac fibroblasts exert beneficial systemic immunomodulatory effects in experimental myocarditis. PLoS One. 2012;7:e41047.
15. Lindner D, Zietsch C, Becher PM, Schulze K, Schultheiss HP, Tschöpe C, Westermann D. Differential expression of matrix metalloproteases in human fibroblasts with different origins. Biochem Res Int. 2012;2012:875742.
16. Mus AM, Cornelissen F, Asmawidjaja PS, van Hamburg JP, Boon L, Hendriks RW, Lubberts E. Interleukin-23 promotes Th17 differentiation by inhibiting T-bet and FoxP3 and is required for elevation of interleukin- 22, but not interleukin-21, in autoimmune experimental arthritis. Arthritis Rheum. 2010;62:1043-1050.
17. Yang Z, Day YJ, Toufektsian MC, Xu Y, Ramos SI, Marshall MA, French BA, Linden J. Myocardial infarct-sparing effect of adenosine A2A receptor activation is due to its action on CD4+ T lymphocytes. Circulation. 2006;114:2056-2064.
18. Hansson GK, Hermansson A. The immune system in atherosclerosis. Nat Immunol. 2011;12:204-212.
19. Gupta S, Pablo AM, Jiang Xc, Wang N, Tall AR, Schindler C. IFN- gamma potentiates atherosclerosis in ApoE knock-out mice. J Clin Invest. 1997;99:2752-2761.
20. Whitman SC, Ravisankar P, Elam H, Daugherty A. Exogenous interferon- gamma enhances atherosclerosis in apolipoprotein E-/- mice. Am J Pathol. 2000;157:1819-1824.
21. Pasqui AL, Di Renzo M, Bova G, Maffei S, Pompella G, Auteri A, Puccetti L. Pro-inflammatory/anti-inflammatory cytokine imbalance in acute coronary syndromes. Clin Exp Med. 2006;6:38-44.
22. Eid RE, Rao DA, Zhou J, Lo SF, Ranjbaran H, Gallo A, Sokol SI, Pfau S, Pober JS, Tellides G. Interleukin-17 and interferon-gamma are produced concomitantly by human coronary artery-infiltrating T cells and act synergistically on vascular smooth muscle cells. Circulation. 2009;119:1424-1432.
23. Yan X, Shichita T, Katsumata Y, Matsuhashi T, Ito H, Ito K, Anzai A, Endo J, Tamura Y, Kimura K, Fujita J, Shinmura K, Shen W, Yoshimura A, Fukuda K, Sano M. Deleterious effect of the il-23/il-17a axis and t cells on left ventricular remodeling after myocardial infarction. J Am Heart Assoc. 2012;1:e004408.
24. Jugdutt BI. Preventing adverse remodeling and rupture during healing after myocardial infarction in mice and humans. Circulation. 2010;122:103-105.
25. Hilfiker-Kleiner D, Hilfiker A, Fuchs M, Kaminski K, Schaefer A, Schieffer B, Hillmer A, Schmiedl A, Ding Z, Podewski E, Podewski E, Poli V, Schneider MD, Schulz R, Park JK, Wollert KC, Drexler H. Signal transducer and activator of transcription 3 is required for myocardial capillary growth, control of interstitial matrix deposition, and heart protection from ischemic injury. Circ Res. 2004;95:187-195.
26. Lindner D, Hilbrandt M, Marggraf K, Becher PM, Hilfiker-Kleiner D, Klingel K, Pauschinger M, Schultheiss HP, Tschöpe C, Westermann D. Protective Function of STAT3 in CVB3-Induced Myocarditis. Cardiol Res Pract. 2012;2012:437623.
27. Nagahama KY, Togo S, Holz O, Magnussen H, Liu X, Seyama K, Takahashi K, Rennard SI. Oncostatin M modulates fibroblast function via signal transducers and activators of transcription proteins-3. Am J Respir Cell Mol Biol. 2013;49:582-591.
28. Das A, Salloum FN, Durrant D, Ockaili R, Kukreja RC. Rapamycin protects against myocardial ischemia-reperfusion injury through JAK2- STAT3 signaling pathway. J Mol Cell Cardiol. 2012;53:858-869.
29. Brereton CF, Sutton CE, Lalor SJ, Lavelle EC, Mills KH. Inhibition of ERK MAPK suppresses IL-23- and IL-1-driven IL-17 production and attenuates autoimmune disease. J Immunol. 2009;183:1715-1723.
30. Xu X, Chen H, Zhu X, Ma Y, Liu Q, Xue Y, Chu H, Wu W, Wang J, Zou H. S100A9 promotes human lung fibroblast cells activation through receptor for advanced glycation end-product-mediated extracellular- regulated kinase ., mitogen-activated protein-kinase and nuclear factor- ?B-dependent pathways. Clin Exp Immunol. 2013;173:523-535.
31. van den Borne SW, Diez J, Blankesteijn WM, Verjans J, Hofstra L, Narula J. Myocardial remodeling after infarction: the role of myofibroblasts. Nat Rev Cardiol. 2010;7:30-37.
32. Cleutjens JP, Verluyten MJ, Smiths JF, Daemen MJ. Collagen remodeling after myocardial infarction in the rat heart. Am J Pathol. 1995;147:325-338.
33. Willems IE, Havenith MG, De Mey JG, Daemen MJ. The alpha-smooth muscle actin-positive cells in healing human myocardial scars. Am J Pathol. 1994;145:868-875.
34. van Nieuwenhoven FA, Turner NA. The role of cardiac fibroblasts in the transition from inflammation to fibrosis following myocardial infarction. Vascul Pharmacol. 2013;58:182-188.
35. Valente AJ, Yoshida T, Gardner JD, Somanna N, Delafontaine P, Chandrasekar B. Interleukin-17A stimulates cardiac fibroblast proliferation and migration via negative regulation of the dual-specificity phosphatase MKP-1/DUSP-1. Cell Signal. 2012;24:560-568.